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Current Status of SCI Research:
Why Capacity is Important
___________________________________________________________________
Never before have so many interventions been under investigation for treating spinal cord
injury (SCI). A number of these treatments are nearing clinical trials. The lack of sufficient
numbers of institutions capable of conducting clinical trials in SCI threatens to slow
progress. Measures to increase capacity for clinical trials in SCI are needed.
There are approximately 250,000 people in the United States living with an SCI. Every
year, another 11,000 people sustain an SCI.1 Although these numbers are small compared
to other health conditions or injuries, the economic consequences of SCI are great –
estimated at over $7.7 billion per year.
Great strides have been made in caring for those with traumatic SCI, resulting in
increased survival and greater life expectancy after SCI. However, little progress has been
made in reducing the neurological deficit or the resulting disability. Functional
expectations today vary little from those published decades ago. This may soon change.
The past decade has seen enormous advances in the area of spinal cord regeneration and
neuroprotection. In the 1990s, clinical trials of methylprednisolone and GM-1 ganglioside
provided hope for improving function for those with SCI. Results, however, were modest
at best. Now, a number of new interventions for acute SCI are ready or nearly ready for
clinical trials. But, because of the relatively low incidence of SCI and the specialized nature
of some of the newer treatments, the research community may not have the capacity to
conduct clinical trials of these interventions.
Many of the treatments being evaluated or developed for acute SCI involve surgical
procedures to place cells or substances within or near the injured spinal cord segment in
order to promote axonal regeneration and tissue sparing. For acute SCI, transplantation of
specialized cells into the spinal cord is often performed in combination with nerve growth
factors.2 Interventions are being developed for chronic SCI, as well. In addition to
pharmacological treatments, researchers are considering combining some of the strategies
used for acute SCI with rehabilitation training.3 Also being conducted are trials of
rehabilitation interventions, such as combining a body weight support harness with
treadmill training to improve ambulation.4
Given the number of acute and chronic interventions for SCI undergoing or nearing clinical
trials, the availability of research capacity in SCI is critical. Clinical trials in acute SCI
require enormous resources. Because of the relatively low incidence of traumatic SCI,
multicenter studies are necessary. The Sygen (GM-1 ganglioside) study required five years
for the 28 participating centers to recruit 760 subjects.5 Less than 25% of patients
screened met the inclusion criteria for the study. The Sygen trial included both complete
and incomplete injuries.
Due to concerns about safety and possible neurological deterioration, initial studies
involving transplants will involve only patients with complete injuries. Even at a busy
center such as ours, which sees over 150 patients per year with acute SCI, less than 10
patients per year would likely qualify for an acute intervention trial limited to those with
complete injuries. Although able to draw from a larger pool of patients, recent
pharmacological intervention studies in chronic SCI have been international in scope in
order to recruit subjects in a reasonable time frame.
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The Model SCI Systems make up a core group of centers with a long history of
collaborative research.6 Our Center has been involved in a number of clinical trials, such
as a phase I clinical trial of Neotrophin in acute SCI, a trial of 4-aminopyridine (a
potassium channel blocker) in chronic SCI, and the recently completed body weightsupported treadmill ambulation training trial in acute SCI.
The ability to conduct a clinical trial requires a core infrastructure of research staff and
strong clinical programs to attract and effectively manage patients. Most centers will only
be able to participate in one acute and one or two chronic trials at a time if they are to
effectively recruit subjects. Target start dates of clinical trials are often missed due to
regulatory delays and logistical difficulties. As a result, there will be gaps in funding for
research staff involved in clinical trials. In the face of shrinking discretionary dollars at
academic institutions, funding to establish and maintain capacity for clinical trials is
needed. Currently, the National Center for Medical Rehabilitation Research (NCMRR),
National Institutes of Health (NIH), funds a traumatic brain injury clinical trials network for
the purpose of maintaining research capacity. It has been suggested that such a network
be established for SCI clinical trials as well, perhaps with collaborative funding from
NCMRR, the National Institute on Disability and Rehabilitation Research (NIDRR) and the
Paralyzed Veterans of America.7
Hopefully, sufficient resources will be dedicated to improving capacity for SCI clinical
trials, so that the promise of basic research can be tested and advances made to restore
function to those with SCI. It would be a tragedy if progress toward a cure for SCI were
hindered because not enough centers caring for those with SCI had the means to
participate in clinical trials. Important

Jefferson is home to the Regional Spinal Cord Injury Center of the Delaware
Valley (RSCICDV), a collaboration between Thomas Jefferson University Hospital
and Magee Rehabilitation Hospital. The RSCICDV has been continuously funded
as a Model SCI System since 1979 by the National Institute on Disability and
Rehabilitation Research, Department of Education. This is one of only 16 such
centers in the United States. Our Center has treated over 3,000 people with SCI
and admits more than 150 new injuries each year. Visit our website at
http://www.spinalcordcenter.org/index.html for more information on the
RSCICDV.
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